SAMe
S-Adenosyl-L-Methionine
Naturally occurring compound with strong evidence for mood support, joint health, and liver function.
SAMe is a molecule naturally produced in the body that's involved in over 100 biochemical reactions including neurotransmitter synthesis, joint cartilage maintenance, and liver detoxification. Clinical evidence supports its use for depression (comparable to some antidepressants), osteoarthritis, and liver conditions. One of the most clinically validated supplements.
Mechanisms of Action
Methyl Donor
Provides methyl groups for critical reactions
Neurotransmitter Support
Supports synthesis of mood-regulating neurotransmitters
Cartilage Support
Supports joint cartilage maintenance
Recommended Dose
400-1600mg for mood; 600-1200mg for joints
Loading: Start at 200-400mg and gradually increase to minimize GI effects
Optimal Timing
- On empty stomach
- Morning and/or midday
Can be taken without food
Best Form
Enteric-coated tablets (SAMe tosylate or butanedisulfonate)
Alternatives: SAMe disulfate
SAMe is unstable — buy enteric-coated from reputable brands. Keep refrigerated. Check expiration dates.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Best absorbed on empty stomach. Avoid evening dosing as it may be energizing. Can take with B12 and folate to support methylation.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Mood Improvement
Significant antidepressant effects
Joint Pain Relief
Reduced osteoarthritis symptoms
Liver Support
Improved liver function in liver disease
Insufficient data; avoid
Avoid — may trigger manic episodes
Who Should NOT Take This
- Bipolar disorder (may trigger mania)
- Parkinson's disease on levodopa
Drug Interactions
Risk of serotonin syndrome — use only under medical supervision
May reduce effectiveness
Increased serotonin syndrome risk
Serotonin syndrome risk
Hypertensive crisis, serotonin syndrome
Possible Side Effects
Tip: Start low, use enteric-coated, take with small snack if needed
Tip: Reduce dose
Tip: Take earlier in day
Tip: Contraindicated in bipolar disorder
Warnings
- Do NOT combine with antidepressants without medical supervision
- May trigger mania in bipolar disorder
- Unstable compound — buy fresh, store properly
- Can be activating — avoid evening dosing
Top studies from 40+ peer-reviewed papers
Lafontant K et al. • Journal of the International Society of Sports Nutrition (2025)
“While there are no differences in percent body fat loss between exercise modes, AT and CT are more effective than RT alone in reducing absolute fat mass; however, RT neither improved nor impeded fat mass loss when incorporated into CT.”
Key Findings:
- CT reduced significantly more fat mass compared to RT (MD: -1.09 kg [95% CI = -0.27 to -1.91]; p = 0.009).
- No significant differences were found between CT, AT, and RT in altering body fat percentage (p > 0.05).
- Under conditions where AT, RT, and CT workloads were matched, similar fat mass, body mass, body fat percentage, and FFM changes were observed between exercise modalities (p > 0.05).
Furukawa Y et al. • BMJ open (2023)
“Shorter treatment duration (3-5 days) probably offers the optimal balance between efficacy and treatment burden for treating CAP in adults if they achieved clinical stability.”
Key Findings:
- We included nine trials (2399 patients with a mean (SD) age of 61.2 (22.1); 39% women).
- The weighted average percentage of the primary outcome in the 10-day treatment arms was 68%.
- Using that average, the absolute clinical improvement rates of the following durations were: 3-day treatment 75% (95% CI: 68% to 81%), 5-day treatment 72% (95% CI: 66% to 78%) and 7-day treatment 69% (95% CI: 61% to 76%).
Lee B et al. • JAMA network open (2023)
“In this NMA, sham acupuncture needling at the same points as those in acupuncture was not a true placebo control for assessing the efficacy of acupuncture for CLBP and might underestimate the outcome of acupuncture in clinical settings.”
Key Findings:
- In comparison with SATS, acupuncture was significantly associated with improvements in both pain (SMD, -0.33; 95% CI, -0.52 to -0.15) and function outcomes (SMD, -0.13; 95% CI, -0.25 to -0.02); however, there were no differences between acupuncture and SATV.
- In comparison with SATS, SATV was significantly associated with better pain (SMD, -0.45; 95% CI, -0.88 to -0.03) and function outcomes (SMD, -0.30; 95% CI, -0.56 to -0.05).
- In this NMA, sham acupuncture needling at the same points as those in acupuncture was not a true placebo control for assessing the efficacy of acupuncture for CLBP and might underestimate the outcome of acupuncture in clinical settings.
Walker KF et al. • The Cochrane database of systematic reviews (2020)
“When compared with placebo, UDCA administered to women with ICP probably shows a reduction in pruritus.”
Key Findings:
- The evidence for fetal distress and stillbirth were uncertain, due to serious limitations in study design and imprecision (risk ratio (RR) 0.70, 95% CI 0.35 to 1.40; 6 trials, 944 women; RR 0.33, 95% CI 0.08 to 1.37; 6 trials, 955 women; GRADE very low certainty).
- When compared with placebo, UDCA administered to women with ICP probably shows a reduction in pruritus.
- However the size of the effect is small and for most pregnant women and clinicians, the reduction may fall below the minimum clinically worthwhile effect.
- The evidence was unclear for other adverse fetal outcomes, due to very low-certainty evidence.
Rutjes AW et al. • The Cochrane database of systematic reviews (2009)
“The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality.”
Key Findings:
- For pain, the analysis indicated a small SMD of -0.17 (95% CI -0.34 to 0.01), corresponding to a difference in pain scores between SAMe and placebo of 0.4 cm on a 10 cm VAS, with no between trial heterogeneity (I(2) = 0).
- For function, the analysis suggested a SMD of 0.02 (95% CI -0.68 to 0.71) with a moderate degree of between-trial heterogeneity (I2 = 54%).
- The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality.
- The effects of SAMe on both pain and function may be potentially clinically relevant and, although effects are expected to be small, deserve further clinical evaluation in adequately sized randomised, parallel-group trials in patients with knee or hip osteoarthritis.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.